Home Prognostic implications of detectable cardiac troponin I below the 99th percentile in patients admitted to an emergency department without acute coronary syndrome
Article
Licensed
Unlicensed Requires Authentication

Prognostic implications of detectable cardiac troponin I below the 99th percentile in patients admitted to an emergency department without acute coronary syndrome

  • Alfredo Bardají EMAIL logo , Gil Bonet , Anna Carrasquer , Maribel González-del Hoyo , Fernando Domínguez , Rafael Sánchez , Carme Boqué and Germán Cediel
Published/Copyright: May 1, 2018

Abstract

Background:

Detectable troponin below the 99th percentile may reflect an underlying cardiac abnormality which might entail prognostic consequences. This study aimed to investigate the prognosis of patients admitted to an emergency department (ED) with detectable troponin below the 99th percentile reference limit who did not present with an acute coronary syndrome (ACS).

Methods:

We analysed the clinical data of all consecutive patients admitted to the ED during the years 2012 and 2013 in whom cardiac troponin was requested by the attending clinician (cTnI Ultra Siemens, Advia Centaur). Patients with troponin below the 99th percentile of the reference population (40 ng/L) and who did not have a diagnosis of ACS were selected, and their mortality was evaluated in a 2-year follow-up.

Results:

A total of 2501 patients had a troponin level below the reference limit, with 43.9% of those showing detectable levels (>6 ng/L and <40 ng/L). Patients with detectable levels were elderly and had a higher prevalence of cardiovascular history and more comorbidities. The total mortality in the 2-year follow-up was 12.4% in patients with detectable troponin and 4.5% in patients with undetectable troponin (p<0.001). In the Cox multivariate regression analysis, the detectable troponin was an independent marker of mortality at 2 years (HR 1.62, 95% CI 1.07–2.45, p=0.021).

Conclusions:

Detectable troponin I below the 99th percentile is associated with higher mortality risk at 2-year follow-up in patients admitted to the ED who did not present with ACS.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Thygesen K, Mair J, Giannitsis E, Mueller C, Lindahl B, Blankenberg S, et al. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J 2012;33:2252–7.10.1093/eurheartj/ehs154Search in Google Scholar PubMed

2. Brush JE, Kaul S, Krumholz HM. Troponin testing for clinicians. J Am Coll Cardiol 2016;68:2365–75.10.1016/j.jacc.2016.08.066Search in Google Scholar PubMed

3. Cediel G, Gonzalez-del-Hoyo M, Carrasquer A, Sanchez R, Boqué C, Bardají A. Outcomes with type 2 myocardial infarction compared with non-ischemic myocardial injury. Heart 2017;103:616–22.10.1136/heartjnl-2016-310243Search in Google Scholar PubMed

4. Bardají A, Cediel GN, Carrasquer A, De Castro RN, Sánchez R, Boqué C. Troponina elevada en pacientes sin síndrome coronario agudo [Troponin elevation in patients without acute coronary syndrome]. Rev Esp Cardiol 2015;68:469–76.10.1016/j.recesp.2014.10.018Search in Google Scholar

5. Pham MX, Whooley MA, Evans GT, Liu C, Emadi H, Tong W, et al. Prognostic value of low-level cardiac troponin-I elevations in patients without definite acute coronary syndromes. Am Heart J 2004;148:776–82.10.1016/j.ahj.2004.03.058Search in Google Scholar PubMed

6. Apple FS, Sandoval Y, Jaffe AS, Ordonez-Llanos J. Cardiac troponin assays: Guide to understanding analytical characteristics and their impact on clinical care. Clin Chem 2017;63:73–81.10.1373/clinchem.2016.255109Search in Google Scholar PubMed

7. Jaffe AS, Ordonez-Llanos J. High-sensitivity cardiac troponin: from theory to clinical practice. Rev Esp Cardiol 2013;66: 687–91.10.1016/j.rec.2013.04.020Search in Google Scholar PubMed

8. Irfan A, Twerenbold R, Reiter M, Reichlin T, Stelzig C, Freese M, et al. Determinants of high-sensitivity troponin t among patients with a non-cardiac cause of chest pain. Am J Med 2012;125:491–8.10.1016/j.amjmed.2011.10.031Search in Google Scholar PubMed

9. Carlson ER, Percy RF, Angiolillo DJ, Conetta DA. Prognostic significance of troponin T elevation in patients without chest pain. Am J Cardiol 2008;102:668–71.10.1016/j.amjcard.2008.04.046Search in Google Scholar PubMed

10. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012;60:1581–98.10.1016/j.jacc.2012.08.001Search in Google Scholar PubMed

11. Wallace TW, Abdullah SM, Drazner MH, Das SR, Khera A, McGuire DK, et al. Prevalence and determinants of troponin T elevation in the general population. Circulation 2006;113:1958–65.10.1161/CIRCULATIONAHA.105.609974Search in Google Scholar PubMed

12. Daniels LB, Laughlin GA, Clopton P, Maisel AS, Barrett-Connor E, Diego S, et al. Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults. Results from the Rancho Bernardo Study. J Am Coll Cardiol 2008;52:450–9.10.1016/j.jacc.2008.04.033Search in Google Scholar PubMed PubMed Central

13. de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. J Am Med Assoc 2010;304:2503–12.10.1001/jama.2010.1768Search in Google Scholar PubMed PubMed Central

14. Daniels LB, Clopton P, DeFilippi CR, Sanchez OA, Bahrami H, Lima JA, et al. Serial measurement of N-terminal pro-B-type natriuretic peptide and cardiac troponin T for cardiovascular disease risk assessment in the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J 2015;170:1170–83.10.1016/j.ahj.2015.09.010Search in Google Scholar PubMed PubMed Central

15. Thorsteinsdottir I, Aspelund T, Gudmundsson E, Eiriksdottir G, Harris TB, Launer LJ, et al. High-sensitivity cardiac troponin I is a strong predictor of cardiovascular events and mortality in the ages-Reykjavik community-based cohort of older individuals. Clin Chem 2016;62:623–30.10.1373/clinchem.2015.250811Search in Google Scholar PubMed PubMed Central

16. Iribarren C, Chandra M, Rana JS, Hlatky MA, Fortmann SP, Quertermous T, et al. High-sensitivity cardiac troponin I and incident coronary heart disease among asymptomatic older adults. Heart 2016;102:1177–82.10.1136/heartjnl-2015-309136Search in Google Scholar PubMed

17. Álvarez I, Hernández L, García H, Villamandos V, López MG, Palazuelos Molinero J, et al. Troponina T ultrasensible en pacientes asintomáticos de muy alto riesgo cardiovascular. Registro TUSARC. Rev Esp Cardiol 2017;70:261–6.10.1016/j.recesp.2016.08.018Search in Google Scholar

18. Love SA, Sandoval Y, Smith SW, Nicholson J, Cao J, Ler R, et al. Incidence of undetectable, measurable, and increased cardiac troponin I concentrations above the 99th percentile using a high-sensitivity vs. a contemporary assay in patients presenting to the emergency department. Clin Chem 2016;62:1115–9.10.1373/clinchem.2016.256305Search in Google Scholar PubMed

19. Reichlin T, Twerenbold R, Reiter M, Steuer S, Bassetti S, Balmelli C, et al. Introduction of high-sensitivity troponin assays: impact on myocardial infarction incidence and prognosis. Am J Med 2012;125:1205–13.10.1016/j.amjmed.2012.07.015Search in Google Scholar PubMed

20. Arenja N, Reichlin T, Drexler B, Oshima S, Denhaerynck K, Haaf P, et al. Sensitive cardiac troponin in the diagnosis and risk stratification of acute heart failure. J Intern Med 2012;271:598–607.10.1111/j.1365-2796.2011.02469.xSearch in Google Scholar PubMed

21. van Wijk S, Jacobs L, Eurlings LW, van Kimmenade R, Lemmers R, Broos P, et al. Troponin T measurements by high-sensitivity vs. conventional assays for risk stratification in acute dyspnea. Clin Chem 2012;58:284–92.10.1373/clinchem.2011.175976Search in Google Scholar PubMed

22. Reed MJ, Mills NL, Weir CJ. Sensitive troponin assay predicts outcome in syncope. Emerg Med J 2012;29:1001–3.10.1136/emermed-2012-201332Search in Google Scholar PubMed

23. Vafaie M, Slagman A, Möckel M, Hamm C, Huber K, Müller C, et al. Prognostic value of undetectable hs troponin T in suspected acute coronary syndrome. Am J Med 2016;129:274–82.10.1016/j.amjmed.2015.10.016Search in Google Scholar PubMed

24. Bandstein N, Ljung R, Johansson M, Holzmann MJ. Undetectable high-sensitivity cardiac troponin T level in the emergency department and risk of myocardial infarction. J Am Coll Cardiol 2014;63:2569–78.10.1016/j.jacc.2014.03.017Search in Google Scholar PubMed

25. Patterson CC, Blankenberg S, Ben-Shlomo Y, Heslop L, Bayer A, Lowe G, et al. Which biomarkers are predictive specifically for cardiovascular or for non-cardiovascular mortality in men? Evidence from the Caerphilly Prospective Study (CaPS). Int J Cardiol 2015;201:113–8.10.1016/j.ijcard.2015.07.106Search in Google Scholar PubMed PubMed Central

26. Welsh P, Hart C, Papacosta O, Preiss D, McConnachie A, Murray H, et al. Prediction of cardiovascular disease risk by cardiac biomarkers in 2 United Kingdom cohort studies: does utility depend on risk thresholds for treatment? Hypertension 2016;67:309–15.10.1161/HYPERTENSIONAHA.115.06501Search in Google Scholar PubMed PubMed Central

Received: 2017-12-06
Accepted: 2018-04-03
Published Online: 2018-05-01
Published in Print: 2018-10-25

©2018 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. New biomarkers and traditional cardiovascular risk scores: any crystal ball for current effective advice and future exact prediction?
  4. Reviews
  5. Laboratory sample stability. Is it possible to define a consensus stability function? An example of five blood magnitudes
  6. Updated review of postmortem biochemical exploration of hypothermia with a presentation of standard strategy of sampling and analyses
  7. Long non-coding RNA-mediated regulation of signaling pathways in gastric cancer
  8. Opinion Paper
  9. Long story short: an introduction to the short-term and longterm Six Sigma quality and its importance in laboratory medicine for the management of extra-analytical processes
  10. EFLM Paper
  11. The European Federation of Clinical Chemistry and Laboratory Medicine syllabus for postgraduate education and training for Specialists in Laboratory Medicine: version 5 – 2018
  12. General Clinical Chemistry and Laboratory Medicine
  13. Early availability of laboratory results increases same day ward discharge rates
  14. Evaluation of the clinical implementation of a large-scale online e-learning program on venous blood specimen collection guideline practices
  15. Improved prospective risk analysis for clinical laboratories compensated for the throughput in processes
  16. National surveys on internal quality control for blood gas analysis and related electrolytes in clinical laboratories of China
  17. Clinical validation of S100B in the management of a mild traumatic brain injury: issues from an interventional cohort of 1449 adult patients
  18. A quantitative LC-MS/MS method for insulin-like growth factor 1 in human plasma
  19. Development and validation of a mass spectrometry-based assay for quantification of insulin-like factor 3 in human serum
  20. Anti-ganglioside antibodies: experience from the Italian Association of Neuroimmunology external quality assessment scheme
  21. Reference Values and Biological Variations
  22. Improving IBD diagnosis and monitoring by understanding preanalytical, analytical and biological fecal calprotectin variability
  23. Establishing normal values of total testosterone in adult healthy men by the use of four immunometric methods and liquid chromatography-mass spectrometry
  24. Cancer Diagnostics
  25. Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases
  26. Cardiovascular Diseases
  27. Prognostic implications of detectable cardiac troponin I below the 99th percentile in patients admitted to an emergency department without acute coronary syndrome
  28. Osteocalcin value to identify subclinical atherosclerosis over atherosclerotic cardiovascular disease (ASCVD) risk score in middle-aged and elderly Chinese asymptomatic men
  29. Infectious Diseases
  30. Comparison of four methods of establishing control limits for monitoring quality controls in infectious disease serology testing
  31. Letter to the Editor
  32. Letter to the Editor relative to Clin Chem Lab Med 2018;56(3):360–372
  33. Update in diagnosis and management of primary aldosteronism: reply to a Letter to the Editor
  34. Can calculated total nitrogen replace Kjeldahl total nitrogen measurements in 24-h urine samples?
  35. Analytical performance of the single well titer function of NOVA View®: good enough to omit ANA IIF titer analysis?
  36. Assessment of Architect cSystems Abbott® for the colorimetric measurement of lithium in urines and dyalisates
  37. β-Trace protein in hemodialysis – comparison of different therapy modalities and high flux dialyzers
  38. Orbitrap™ high-resolution mass spectrometry for the identification of amoxicillin crystalluria
  39. High fluorescence cell count in ascitic body fluids for carcinomatosis screening
  40. The International Society for Enzymology: a glorious history, a golden legacy
  41. Congress Abstracts
  42. 10th National Congress of the Portuguese Society of Clinical Chemistry, Genetics and Laboratory Medicine
  43. 5th EFLM-UEMS European Joint Congress in Laboratory Medicine
Downloaded on 9.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2017-1140/html
Scroll to top button